In The News Posted April 22, 2022 Share Posted April 22, 2022 AUSTIN, Texas, 22 de abril de 2022 /PRNewswire/ -- A Direct Biologics, uma empresa de biotecnologia regenerativa com uma inovadora tecnologia de plataforma de vesícula extracelular (VE), anunciou hoje que a FDA autorizou a empresa a prosseguir com seu estudo clínico de Fase 3 utilizando...View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now